Nabriva Therapeutics plc
OTC: NBRVF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- H. Michael Hogan
- Employees
- 39
- Headquarters
- Dublin, Ireland
- IPO year
- 2023
- Market cap
- $323.0
- Website
- https://www.nabriva.com
Loading NBRVF…
Loading profile data…Frequently asked questions about NBRVF
What does Nabriva Therapeutics plc (NBRVF) do?
Nabriva Therapeutics plc is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative anti-infective medicines for managing serious infections. Its current portfolio includes SIVEXTRO, an oxazolidinone-class antibacterial utilized for acute bacterial skin and skin structure infections (ABSSSI). Another key pro...
Where does NBRVF trade?
Nabriva Therapeutics plc (NBRVF) trades on the Other OTC.
What sector is NBRVF in?
Nabriva Therapeutics plc (NBRVF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Nabriva Therapeutics plc?
H. Michael Hogan is the chief executive officer of Nabriva Therapeutics plc (NBRVF).
Where is Nabriva Therapeutics plc headquartered?
Nabriva Therapeutics plc is headquartered in Ireland.
Does NBRVF pay a dividend?
Nabriva Therapeutics plc (NBRVF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NBRVF go public?
Nabriva Therapeutics plc (NBRVF) completed its initial public offering in 2023.